Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
NCT07102394Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec in neurofibromatosis type 1 (NF1) and cutaneous neurofibroma (cNF), sponsored by Johns Hopkins University. Primary endpoints: Feasibility of IMLYGIC at 1 year and Tolerability of IMLYGIC at 1 year. Started Feb 2026; status: recruiting.
02
Drugs
talimogene laherparepvec
03
Conditions
neurofibromatosis type 1 (NF1)cutaneous neurofibroma (cNF)
Beyond the preview
Go deeper on NCT07102394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102394.